Asco Gu 2023 A Phase Ii Trial Modifying Metabolic Syndrome And Tps273 background: prostate cancer is a disease of older age, and there is significant overlap with age related illnesses. androgens play a critical role in prostate cancer but also have been linked to cardiovascular (cv) disease, metabolic syndrome, bone health, and frailty. adt is associated with an increased risk of cv events primarily due to increased rates of diabetes, dyslipidemia, and. Tps273 trials in progress poster session a phase ii trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on adt using a risk factor modification program and continuous fitbit monitoring (protrio). andrew warren hahn, rebecca slack tidwell, whittney thoman, amer abdulla,.
Asco Gu 2023 Treatment Free Survival Outcomes From The Phase Ii Study Dr. andrew hahn presented the study design for the protrio trial, a phase ii trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on androgen deprivation therapy using a risk factor modification program and continuous fitbit® monitoring. Methods: this single center, open label, randomized phase ii trial is evaluating a 16 week digital risk factor modification program, which includes an exercise prescription (150 minutes of titrated cardiovascular exercise and resistance exercise 2 times a week) with support via a smart phone application (moving analytics) and fitbit, in. Methods: this single center, open label, randomized phase ii trial is evaluating a 16 week digital risk factor modification program, which includes an exercise prescription (150 minutes of. September 10, 2023. presented here are some brief summaries of novel therapies under study from the 2023 asco breakthrough meeting in yokohama, japan. the subjects range from new observations about a her2 directed bispecific antibody and systemic treatment of gastric cancer to an option for treating hand foot syndrome in patients on capecitabine.
Comments are closed.